Compare MSGM & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSGM | NEUP |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 18.5M |
| IPO Year | 2020 | 2002 |
| Metric | MSGM | NEUP |
|---|---|---|
| Price | $5.32 | $3.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 92.3K | 11.4K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | $741,000.00 | ★ $1,174,165.00 |
| Revenue This Year | $36.75 | N/A |
| Revenue Next Year | $51.04 | N/A |
| P/E Ratio | $40.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.11 | $3.19 |
| 52 Week High | $5.78 | $17.90 |
| Indicator | MSGM | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 63.51 | 22.78 |
| Support Level | $3.62 | $3.28 |
| Resistance Level | $5.61 | $3.86 |
| Average True Range (ATR) | 0.30 | 0.07 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 89.47 | 5.27 |
Motorsport Games Inc is a racing game developer, publisher, and esports ecosystem provider of official motorsport racing series, including games based on the 24 Hours of Le Mans endurance race (Le Mans) and the associated FIA World Endurance Championship (the WEC). Its portfolio also includes the KartKraft karting simulation game, as well as Studio 397 B.V. (Studio397) and their rFactor 2 realistic racing simulator technology and platform. The games are developed and published for personal computers (PCs) through various digital channels, including full-game and downloadable content (DLC). Additionally, Motorsport Games organizes esports tournaments, competitions, and events. Its reportable segments are: Gaming, which generates the maximum revenue, and Esports.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.